Document is current
Any future updates will be listed below
-
Authors
Zare, Abdolhossein
Salehi, Saeede
Bader, Jakob M.
Wiessler, Anna-Lena
Prokesch, Manuela
Albrecht, Vincent
Villmann, Carmen
Mann, Matthias
Briese, Michael
Sendtner, Michael https://orcid.org/0000-0002-4737-2974
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (BR4910/2–2)
Deutsche Forschungsgemeinschaft (SE697/5–2)
Hermann und Lilly Schilling-Stiftung für Medizinische Forschung
Stiftung VERUM
Universitätsklinikum Würzburg
- License Information
-
More Information
Article History
Received: 10 September 2024
Accepted: 27 June 2025
First Online: 29 July 2025
Declarations
:
: The experimental procedures in this study involving mice were performed according to the regulations on animal protection of the German federal law and the Association for Assessment and Accreditation of Laboratory Animal Care, in agreement with and under the control of the local veterinary authority.
: Not applicable.
: Abdolhossein Zare, Saeede Salehi, Michael Briese and Michael Sendtner are listed as inventors on a US provisional patent application titled “Method and molecules for reducing axonal tau protein accumulation through blocking of hnRNP R-mediated MAPT mRNA transport for treatment of Alzheimer’s disease” filed by the University of Wuerzburg, Germany, that covers the use of the MAPT-ASOs and of hnRNP R depletion for treatment of Alzheimer’s disease.
